Liposomal doxorubicin is less cardiotoxic than epirubicin in patients with breast cancer: evidence from a randomized clinical trial employing biological, tissue Doppler and standard echocardiographic endpoints.

M Lotrionte, G Palazzoni, G Comerci, A Abbate, G Biondi-Zoccai
  • Cancer Research, January 2009, American Association for Cancer Research (AACR)
  • DOI: 10.1158/0008-5472.sabcs-6145

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1158/0008-5472.sabcs-6145

The following have contributed to this page: Prof. Giuseppe Biondi-Zoccai